Radiolabeled Somatostatin Analogues Therapy in Advanced Neuroendocrine Tumors: A Single Centre Experience

Abstract

The aim of this study was to assess the efficacy of PRRT in patients with advanced neuroendocrine tumors (NETs). Patients and Methods. From January 2007 to August 2011, we enrolled 65 patients (m/f 38/27; mean age 65 years, range 33–83) with advanced NETs having enhanced SSTR expression, treated with PRRT. The enhanced expression of SSTR was assessed using 68Ga-DOTATOC/DOTATATE PET/CT. Among all the enrolled patients, 6 of them were excluded from the present analysis since they voluntarily interrupted treatment. Mean activity/cycle of 2.6 GBq (90Y-DOTATOC/DOTATATE) or 6.0 GBq (177Lu-DOTATOC/DOTATATE) was administrated intravenously (max 9 cycles). Results. Complete response (CR) was found in 1/59 (2%) patients, partial remission (PR) in 24/59 (40.5%) patients, stable disease (SD) in 24/59 (40.5%), and progression (PD) in 10/59 (17%) patients. The overall tumor response rate (CR + PR) was 42.5%. In 40.5% of patients, the disease could be stabilized. Overall, 49 out of 59 patients had no tumor progression (83%). Twelve patients out of 59 (20%) had grade 2-3 hematological side effects including anemia, thrombocytopenia, and leukopenia. Long-term nephrotoxicity was observed in 3 patients (2 moderate, 1 severe). Conclusions. PRRT is a promising perspective for patients with advanced NETs.

Kidney Dosimetry in177Lu and90Y Peptide Receptor Radionuclide Therapy: Influence of Image Timing, Time-Activity Integration Method, and Risk Factors

“…Toxicity was recorded throughout all the study and up to 6 months after completion. A comprehensive description of this clinical study and patients is reported in a companion paper [13]. …”

Zalecenia ogólne dotyczące postępowania w nowotworach neuroendokrynnych układu pokarmowego (rekomendowane przez Polską Sieć Guzów Neuroendokrynnych)

“…90 Y, or a combination of the two. Data from nonrandomised clinical studies indicates that a response to treatment (complete or partial remission) can be achieved in approximately 8-46% of patients, and the mean progression-free survival after the treatment is 25 to 36 months [133][134][135][136][137][138][139][140][141]. These studies apply mostly to patients with well-differentiated neoplasms (G1 and G2), and these recommendations are for this group of patients.…”

“…In patients with a high somatostatin receptor expression, depending on the stage of the disease, PPRT may be considered as the first-line treatment [138,140].…”

Somatostatin receptor positron emission tomography/computed tomography imaging in Merkel cell carcinoma

“…Positron emission tomography/computed tomography was performed on a hybrid scanner (Discovery STE; GE Healthcare, Chalfont St. Giles, UK in Centre A and Gemini GXL; Philips Medical Systems, Cleveland, OH or Biograph; Siemens Healthcare, Malvern, PA in Centre B). Images were acquired 60 ± 10 min after tracer injection (2 MBq/kg) as whole body (vertex‐feet) in both Centres according to protocols previously described …”